illustrated that rosiglitazone in combination with gemcitabine could regulate T-cell populations by increasing circulating CD8+ T cells and intra-tumor CD4+ cells and CD8+ T cells, thereby reducing the progression and metastasis of pancreatic tumor, and further enhancing cell apoptosis (60). Here, CD8A is linked to neoplasm.